Neue Novavax: Anstieg nach 1:20 Re-Split

and Johnson Johnson vaccines in July

Georgia expects to receive the Novavax and Johnson Johnson Covid-19 vaccines from the COVAX platform in July, Deputy Health Minister Tamar Gabunia said, reports citing .

''We will be able to mobilize additional doses of Sinopharm in a short time. We have the Sinovac vaccine and expect Novavax and Johnson&Johnson Covid-19 jabs from the COVAX platform, presumably in July.

The process is quite active. A daily vaccination number is 5,000. It is a good indicator'', Tamar Gabunia said.


https://menafn.com/1102065812/...211oUdSkhfLwjjDUFeMvndPKI7bAcOSimslo
 

Five things to know about: Mixing and matching coronavirus vaccines

... But it’s possible for the immune system to develop a response against the adenovirus platform. This is not dangerous, says Prof. Dosenovic, but it could dampen the vaccine’s effect.

To get around this possible risk, Prof. Dosenovic says Sputnik V uses a different adenovirus in each shot, and AstraZeneca uses one from chimpanzees that our systems have never encountered.

Prof. Dosenovic says getting a third shot - which is possible if vaccines are updated to address variants - with a viral vector vaccine would not be optimal. From this perspective, it makes sense to change platforms to mRNA or one that is protein-based like Novavax.

https://horizon-magazine.eu/article/...H0xCqLIvZ5hey-mfZjEuA0z01sQfOk  

9.35 million Covid vaccine doses to reach Netherlands by end-June despite Janssen delay

... De Jonge predicted that no new vaccines will be granted market approval in time for new players to make deliveries by the end of the second quarter. Talks with Curevac and GSK/Sanofi are productive and ongoing, and an advance purchase deal may be closed with Novavax.

https://nltimes.nl/2021/05/12/...WcIifXSyxNgeBNytktEA1aV1R_9NmBSLJmuE  

noch lange nicht vorbei.



Mutation B.1.617

Die WHO stuft die in Indien grassierende Mutation B.1.617 als "besorgniserregend" ein. Nun wird sie in immer mehr Ländern nachgewiesen. In Europa ist ein Land besonders stark betroffen.


https://www.n-tv.de/panorama/...FnNU9SZDFOB4Rmhfxw#Echobox=1620802282  

Bei der Pressekonferenz, dass sich die EU weiterhin in Verhandlungen mit Novavax befindet.  

JPMorgan analyst Eric Joseph downgraded Novavax (NASDAQ: NVAX) from Overweight to Neutral with a price target of $161.00 (from $285.00).

https://www.streetinsider.com/dr/...F1KaZ4mXIQ5rH1Gsz8r3q0TDZCisDONI4  

HC Wainwright & Co. reiterated coverage of Novavax with a rating of Buy and set a new price target of $294.00 from $317.00 previously

https://www.streetinsider.com/Analyst+PT+Change/...ACz2_B-t5gB8gjRKJU
 

... Auch Forscher der Universität Oxford testen derzeit, wie das Mischen von Vakzinen funktionieren kann. Die Studie, Com-CoV genannt, bietet den Teilnehmern eine erste Dosis mit dem Vakzin von Biontech/Pfizer oder von Astrazeneca. Für die zweite Dosis erhalten sie entweder den gleichen Impfstoff oder eine Spritze mit Moderna oder Novavax.

https://www.n-tv.de/wissen/...I4xeTYLxbF7ZI12t6RNk#Echobox=1620834368

Com-Cov vaccine trial to include Moderna and Novavax
(14.04.21)

https://www.nationalhealthexecutive.com/articles/...derna-and-novavax  

das Bloomberg Interview vom 12.05.21 mit Stan ist schon bekannt, poste es hier aber trotzdem:

https://www.bloomberg.com/news/videos/2021-05-12/...-filing-ceo-video

Der Kurseinbruch wird nur von kurzer Dauer sein, denn hier hat man mit der Angst der Anleger gespielt, jedes andere Unternehmen wäre bei dieser Nachrichtenlage und der Verzögerung nicht so abgestraft worden.
Alles wie immer nur meine Meinung.


 

da könntest du absolut recht haben , habe mein Invest vor einiger Zeit um 80% reduziert ,
bin aber noch gut dabei
allen noch einen guten Herrentag  

sind erst 4% der japanischen Bevölkerung geimpft. Dazu folgende Nachricht aus dem Yahoo Forum :

Japan earmarks 512 bil. yen from reserve funds to buy more vaccines

Thu May 13 20:57:06 2021 EDT
Japan's Cabinet on Friday decided to earmark 512 billion yen ( $4.7 billion ) of the fiscal 2021 reserve funds to purchase more COVID-19 vaccines as infections continue to increase in the country.
The outlay will be put toward securing 250 million doses in total from U.S. firms Pfizer Inc. , Moderna Inc. and Novavax Inc. amid intensifying global competition for vaccines.
Prime Minister Yoshihide Suga said last week the government is in talks with Moderna and Novavax for 200 million doses of vaccine to be administered next year.
Of the total, Pfizer is expected to supply 50 million doses from July through September.
Relying on imports for its COVID-19 vaccine supply, Japan began inoculating seniors aged 65 or older, a group that accounts for nearly 30 percent of its population of 126 million, in mid-April after starting its campaign with health care workers in February.
Following the regulator's green light for the Pfizer shot in February, the Ministry of Health, Labor and Welfare is planning to begin formal procedures for approval of vaccines developed by Moderna and British drugmaker AstraZeneca Plc , making them the second and third available in Japan .
The government has set aside 5 trillion yen in reserve funds to deal with the pandemic under the 106.61 trillion yen initial budget for fiscal 2021 starting in April. Following Friday's Cabinet approval, 3.99 trillion yen remains.
In fiscal 2020, a total of 11.5 trillion yen was allocated in virus reserve funds under two extra budgets. Almost all was used, with just 508 billion yen left.  

https://mobile.twitter.com/AlYap73961573/status/1393157061605830657

Zulassung Südkorea bereits im Mai??  

In Indien werden derzeit zwei Impfstoffe, Covaxin von Bharat Biotech aus Hyderabad und Covishield von Oxford-AstraZeneca, in einer landesweiten Impfaktion verabreicht. Der russische Anti-Covid-Impfstoff Sputnik V wird voraussichtlich ab nächster Woche verfügbar sein.

Die Regierung hat einen Anstoß zur Erhöhung der Impfstoffproduktion gegeben und eine Notfallzulassung an Biological E, Zydus Cadila, Serum Institute of India für Novavax, den nasalen Impfstoff von Bharat Biotech, Gennova und Sputnik V erteilt.  

zu Unicorn71 Post:

https://www.indiatoday.in/coronavirus-outbreak/...-1802668-2021-05-14

 

 

The government has given a push to increase vaccine manufacturing and has issued emergency use authorisation to Biological E, Zydus Cadila, Serum Institute of India for Novavax, Bharat Biotech's nasal vaccine, Gennova and Sputnik V.

https://www.news18.com/news/india/...-they-how-they-work-3735575.html  

... GlobalData forecast Novavax’s vaccine will generate $33.3 billion from expected authorization this spring through 2027. A peak forecast of $7.2 billion is expected in 2027 alone, according to the report.

... Keshalini Sabaratnam, a GlobalData Analyst, said efficacy demonstrated by Novavax’s vaccine candidate against the original strain of the virus is on par with the leading COVID-19 vaccines developed by Moderna and Pfizer, and BioNTech. Additionally, Sabaratnam noted the Novavax efficacy against the U.K. strain should boost sales in those countries due to the prevalence of that particular form of the COVID-19 virus.

... “If NVX-CoV2373 receives approval, it will contribute toward boosting the vaccine roll-out across multiple geographies in H2 (second half of 2021), which will help bring the pandemic under control,” Sabaratnam said in a statement.

https://biobuzz.io/...7kEnZQ2CuwDxKfnT7zE34-mP4x3Cpq6HyHX2NIn4KFC3PKM  

SK bioscience's COVID-19 vaccine plant in South Korea gets European nod

SEOUL, May 17 (Reuters) - South Korea’s SK bioscience said on Monday its COVID-19 vaccine facility had received European Union Good Manufacturing Practices (GMP) certification, paving the way for exports to the bloc.

The certification approves the production and processing line and quality system of SK bioscience’s Andong plant, which produces COVID-19 vaccines developed by AstraZeneca Plc and Novavax Inc. It will enable SK to export vaccines to the European markets.

SK bioscience is also looking to obtain the Current Good Manufacturing Practice regulations enforced by the U.S. Food and Drug Administration, it said in a statement.

It has been supplying the AstraZeneca vaccine it has produced to the domestic market and the global vaccine sharing facility COVAX.

SK bioscience also has a license agreement with Novavax to produce 40 million COVID-19 vaccine doses for South Korea as well as a contract development and manufacturing deal for global supply.

“The global vaccine demand is expected to surge explosively driven by the pandemic ... Based on the globally recognised high-level technology, we will accelerate our business expansion,” SK bioscience CEO Ahn Jae-yong said in a statement.

https://www.reuters.com/article/...outhkorea-skbioscien-idUSL3N2N40W5  

Novavax vaccine: 'High degree of confidence' Billingham-made covid jab will work against variants

..."And in fact, one of its attractions is that it has this broad coverage, not just against the variant that it was precisely designed to deal with, but a wide range of variants too.

"That is part of the theory of the technology that underpins that particular vaccine - it's a very modern vaccine, it's very exciting.

"And it's terrific that it's been made on Teesside."


https://www.gazettelive.co.uk/news/teesside-news/...nfidence-20624793  

World-first COVID-19 vaccine booster study launches in UK

... Vaccines being trialled include Oxford/AstraZeneca, Pfizer/BioNTech, Moderna, Novavax, Valneva, Janssen and Curevac, as well as a control group. The trial has received ethics approval by the NHS Research Ethics Committee, as well as approval from the Medicines and Healthcare products Regulatory Agency.


https://www.gov.uk/government/news/...fXlRnf79oHXgP91Bn-yZosZHtBWb4Bk  

https://www.novavax.com/sites/default/files/...vestorDeck-May2021.pdf  

Novavax could have the ‘best’ COVID-19 shot, but new delays are raising questions about the $10 billion biotech’s path to profits

•Novavax has transformed as its experimental coronavirus vaccine nears an FDA green light.

•But the biotech recently disclosed delays to the timeline in getting the shot to market.

•Novavax’s backers are confident the biotech will still have a sizable influence on COVID-19.

... Peter Kolchinsky, a founder and managing partner at the biotech investing firm RA Capital, led a $200 million investment in Novavax in June that has paid off big. He stands by essentially the same investment case he made then: This virus is here to stay, booster shots are coming, and Novavax’s platform is well-suited to meet that moment.

The earlier clinical data has bolstered Kolchinsky’s confidence in Novavax because it shows the shot produces high antibody levels and fewer, less-intense side effects than Pfizer’s and Moderna’s vaccines. Side effects from Novavax’s shot were “predominantly mild to moderate and transient,” study researchers said in The New England Journal of Medicine.

... RA Capital founder and managing partner Peter Kolchinsky.

Peter Kolchinsky

“We think they have the best booster vaccine,” Kolchinsky told Insider in a statement.

“And since it looks like we’ll be getting COVID boosters regularly, as we do for flu, having a good, tolerated vaccine that won’t leave people talking about side-effects, as current COVID vaccines do, is important,” he added. “While the delays feel long in the moment, we’re used to drug development taking many years, so a few quarters delay is modest in the grand scheme of things.”

https://newsotime.com/...out-the-10-billion-biotechs-path-to-profits/  

Novavax could have the ‘best’ COVID-19 shot, but new delays are raising questions about the $10 billion biotech’s path to profits

Gibt es neue Verzögerungen oder handelt es sich in dem Beitrag um die hinlänglich bekannten? Wie interpretierst Du das?  

gute Frage, ich denke es hat mit dem Exportverbot aus Indien zu tun.

https://www.reuters.com/world/india/...orts-until-october-2021-05-18/

Man vermutet ja dass das schon länger bekannt war und Stan sich deshalb mit Herrn Moon (SK Bioscience) in Südkorea getroffen hat. Ich denke hier läuft vieles im Hintergrund speziell in Bezug auf die Kampagne COVAX.  

Du meinst, weil Indien das Exportverbot verfügt hat, soll jetzt über SK Bioscience die Produktion und Lieferung an das COVAX Programm erfolgen? Inklusive der Vakzine für Südkorea? Ordne ich das richtig ein?

Von dem Treffen Biden /Moon habe ich gehört, auch das Novavax dabei eine gewichtige Rolle spielt, aber den Zusammenhang mit Indien sah ich bisher nicht. Sehr erhellend :0) Dankeschön!